<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166060</url>
  </required_header>
  <id_info>
    <org_study_id>IvaCRT KB/111/2014</org_study_id>
    <nct_id>NCT02166060</nct_id>
  </id_info>
  <brief_title>Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy</brief_title>
  <acronym>IvaCRT</acronym>
  <official_title>Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the role of ivabradine in cardiac resynchronization
      recipients with an unsatisfactory percentage biventricular pacing.

      The study protocol 60 patients with heart failure NYHA (New York Heart Association) II-IV
      treated with optimal medical therapy as clinically indicated who received CRT-D device more
      than 3 months ago. Patients with biventricular pacing &lt;95% will and heart rate &lt;70 at rest
      and &gt;50% of heart rate in device memory &gt;70 will receive ivabradine. The minimal follow-up of
      patients in the study will be at least six months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 30% of CRT recipients do not respond to therapy. One of the causes ot that is
      unsatisfactory percentage of biventricular pacing. Patients may loose biventricular pacing
      because of inadequate sinus tachycardia.

      Ivabradine may prevent inadequate sinus tachycardia and improve quality of live of CRT
      recipients.

      According to current guidelines ivabradine is recommended in patients with symptomatic heart
      failure with heart rate at rest &gt;70.

      The hypothesis of this study is that ivabradine may increase percentage of biventricular
      pacing in CRT recipients who have unsatisfactory percentage of biventricular pacing and &gt;50%
      of heart rate in device memory &gt;70.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of biventricular pacing &gt;95%</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of biventricular pacing &gt;98%</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first inappropriate shock</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of mean heart rate compared with baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular hospitalization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change between baseline and final echocardiographic parameters</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of quality of life (SF36)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change between baseline and final NYHA class</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivabradine 5 mg twice a day or 7,5 mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine 5 mg twice a day or 7,5 mg twice a day</description>
    <arm_group_label>Ivabradine</arm_group_label>
    <other_name>Procoralan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  heart failure NYHA II-IV

          -  left ventricular ejection fraction =&lt;35%

          -  CRT-D implanted over 3 months ago

          -  optimal CRT-D parameters

          -  biventricular pacing &lt;95% despite the optimal parameters of the device

          -  optimal pharmacotherapy with the highest well-tolerated beta-adrenolytic dosage

          -  heart rate at rest below 70 bpm

          -  over 50% of heart rhythm over 70 bpm at interrogation with the device

        Exclusion Criteria:

          -  persistent atrial fibrillation/flutter

          -  device associated ineffective resynchronization

          -  contraindications to ivabradine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcin Grabowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcin Grabowski, PhD</last_name>
    <phone>+48 660 751 816</phone>
    <email>marcin.grabowski@wum.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lukasz Januszkiewicz, MD</last_name>
    <phone>+48 694 333 056</phone>
    <email>lukasz.jan.januszkiewicz@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>1st Department of Cariology of Medcial University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcin Grabowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>June 13, 2014</last_update_submitted>
  <last_update_submitted_qc>June 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Marcin Grabowski</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

